Hayley Suen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1697087/publications.pdf

Version: 2024-02-01

1307594 1281871 14 331 7 11 citations g-index h-index papers 14 14 14 947 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer Journal, 2020, 10, 37.	6.2	24
2	The T Cell in Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 537-542.	0.4	43
3	Isolation of Human CD138+ Microparticles from the Plasma of Patients with Multiple Myeloma. Neoplasia, 2016, 18, 25-32.	5.3	54
4	A CD2 highâ€expressing stressâ€resistant human plasmacytoid dendriticâ€cell subset. Immunology and Cell Biology, 2016, 94, 447-457.	2.3	34
5	A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia. Blood, 2016, 128, 5221-5221.	1.4	1
6	Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. Leukemia and Lymphoma, 2015, 56, 2714-2716.	1.3	2
7	Phospho-Flow Cytometry Quantitation of STAT Signalling Checkpoints in Malignant and Non-Malignant Cells Identifies Patients Suitable for pSTAT3 and 5 Targeted Inhibitors. Blood, 2015, 126, 5356-5356.	1.4	O
8	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 2014, 55, 1090-1098.	1.3	66
9	Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy. Blood, 2014, 124, 3367-3367.	1.4	3
10	Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. Oncolmmunology, 2012, 1, 1658-1660.	4.6	21
11	CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood, 2012, 120, 2055-2063.	1.4	82
12	Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro. Blood, 2012, 120, 3950-3950.	1.4	1
13	Ten Year Survival in Patients with Myeloma Is Characterized by the Persistence of Immunological Control Which Is Detected by Immunological Biomarkers. Blood, 2012, 120, 1818-1818.	1.4	0
14	Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy,. Blood, 2011, 118, 3924-3924.	1.4	0